Skip to main content

Evidence to Improve Care

Interferon-Gamma Release Assay Testing for Latent Tuberculosis Infection

 

Draft Recommendation

  • Ontario Health, based on guidance from the Ontario Health Technology Advisory Committee, recommends publicly funding interferon gamma release assay (IGRA) testing for latent tuberculosis infection.

Read the draft recommendation report

Thank you for your comments.

The public feedback period for this topic has ended. All comments will be considered before a final recommendation is made and posted here. Use the tabs below to learn more about this topic and download supporting draft documents, including the full assessment report.


Tuberculosis (TB) is a disease caused by bacteria that primarily affects the lungs and can be spread through an infected person’s breath, especially through coughing or speaking. Symptoms include respiratory distress, organ failure and eventual death, but is curable when caught and treated early. Many people infected with TB bacteria experience a symptomless, inactive stage of infection. This stage is known as “latent tuberculosis infection” (LTBI). Screening for – and treating people with – LTBI can reduce the risk of symptoms appearing and spreading TB to others.

The interferon-gamma release assay (IGRA) can determine if an individual has been exposed to the bacteria that causes TB. This technology involves testing a blood sample for an immune system response in a laboratory. Currently in Ontario, only the tuberculin skin test (TST) is publicly funded as a test for LTBI. The IGRA test is considered an acceptable alternative to the TST for people who may have LTBI by the Canadian Tuberculosis Standards, published in 2022.

This health technology assessment looked at how accurate and cost-effective IGRA testing is for LTBI. It also evaluates the budget impact of publicly funding IGRA. We reached out to people with LTBI to learn about their experiences, preferences, and values, but were unable to complete interviews. Instead, we spoke to 53 health care providers who prescribe and rely on the results of TB tests.

Read the full health technology assessment report for more information.

Interferon-Gamma Release Assay Testing for Latent Tuberculosis Infection: A Health Technology Assessment
September 2024

Use of this site, and the interpretation of the information contained here, is subject to important terms and conditions. Use of this site and information except in accordance with these terms and conditions is expressly prohibited.

We reviewed evidence on interferon-gamma release assay testing for latent tuberculosis infection. Read the latest draft recommendation and share your feedback.


Submit Feedback


Date posted: September 4, 2024
Closing date for public comment: September 25, 2024



Let’s make our health system healthier

Join Our Patient, Family and Public Advisors Program

Patients, families and the public are central to improving health quality.


Man smiling

Sign up for our newsletter

Are you passionate about quality health care for all Ontarians? Stay in-the-know about our newest programs, reports and news.

Health Quality Connect - Health Quality Ontario's newsletter - on an iPad and a cell phone